论文部分内容阅读
Pembrolizumab(pembro)plus ipilimumab(ipi)for advanced melanoma:Results of the KEYNOTE-029 expansion
【作 者】
:
【机 构】
:
Melanoma Institute Australia,The University of Sydney,Mater Hospital,and Royal North Shore Hospital,
【出 处】
:
2016年临床肿瘤学新进展学术研讨会
【发表日期】
:
2016年5期
其他文献
Randomized phase Ⅲ study on the effect of early intensification of rituximab in combination with 2-w
会议
A prospective,multicenter,randomized study of anti-CCR4 monoclonal antibody mogamulizumab(moga)vs in
会议
PILLAR-2:A randomized,double-blind,placebo-controlled,phase Ⅲ study of adjuvant everolimus(EVE)in pa
会议
Two years rituximab maintenance vs.observation after first-line treatment with bendamustine plus rit
会议
Upfront autologous stem cell transplantation(ASCT)versus novel agent-based therapy for multiple myel
会议
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOT
会议
Overall survival(OS)in patients(pts)with platinum-sensitive relapsed serous ovarian cancer(PSR SOC)r
会议